Literature DB >> 31028823

Delineation of crosstalk between HSP27 and MMP-2/MMP-9: A synergistic therapeutic avenue for glioblastoma management.

Y Rajesh1, Anupam Banerjee2, Ipsita Pal1, Angana Biswas1, Subhayan Das1, Kaushik Kumar Dey3, Neelkamal Kapoor4, Ananta Kumar Ghosh5, Pralay Mitra6, Mahitosh Mandal7.   

Abstract

BACKGROUND: Epithelial to mesenchymal transition (EMT) and extracellular matrix (ECM) remodeling, are the two elemental processes promoting glioblastoma (GBM). In the present work we propose a mechanistic modelling of GBM and in process establish a hypothesis elucidating critical crosstalk between heat shock proteins (HSPs) and matrix metalloproteinases (MMPs) with synergistic upregulation of EMT-like process and ECM remodeling.
METHODS: The interaction and the precise binding site between the HSP and MMP proteins was assayed computationally, in-vitro and in GBM clinical samples.
RESULTS: A positive crosstalk of HSP27 with MMP-2 and MMP-9 was established in both GBM patient tissues and cell-lines. This association was found to be of prime significance for ECM remodeling and promotion of EMT-like characteristics. In-silico predictions revealed 3 plausible interaction sites of HSP27 interacting with MMP-2 and MMP-9. Site-directed mutagenesis followed by in-vitro immunoprecipitation assay (IP) with 3 mutated recombinant HSP27, confirmed an interface stretch containing residues 29-40 of HSP27 to be a common interaction site for both MMP-2 and MMP-9. This was further validated with in-vitro IP of truncated (sans AA 29-40) recombinant HSP27 with MMP-2 and MMP-9.
CONCLUSION: The association of HSP27 with MMP-2 and MMP-9 proteins along with the identified interacting stretch has the potential to contribute towards drug development to inhibit GBM infiltration and migration. GENERAL SIGNIFICANCE: Current findings provide a novel therapeutic target for GBM opening a new horizon in the field of GBM management.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Glioblastoma; HSP27; MMP-2; MMP-9; Therapeutic target

Year:  2019        PMID: 31028823     DOI: 10.1016/j.bbagen.2019.04.015

Source DB:  PubMed          Journal:  Biochim Biophys Acta Gen Subj        ISSN: 0304-4165            Impact factor:   3.770


  11 in total

Review 1.  Molecular Chaperones in Cancer Stem Cells: Determinants of Stemness and Potential Targets for Antitumor Therapy.

Authors:  Alexander Kabakov; Anna Yakimova; Olga Matchuk
Journal:  Cells       Date:  2020-04-06       Impact factor: 6.600

Review 2.  Antiangiogenic Targets for Glioblastoma Therapy from a Pre-Clinical Approach, Using Nanoformulations.

Authors:  Gabriel Nery de Albuquerque Rego; Arielly da Hora Alves; Mariana Penteado Nucci; Javier Bustamante Mamani; Fernando Anselmo de Oliveira; Lionel Fernel Gamarra
Journal:  Int J Mol Sci       Date:  2020-06-24       Impact factor: 5.923

Review 3.  Current and Future Trends on Diagnosis and Prognosis of Glioblastoma: From Molecular Biology to Proteomics.

Authors:  Artemiy S Silantyev; Luca Falzone; Massimo Libra; Olga I Gurina; Karina Sh Kardashova; Taxiarchis K Nikolouzakis; Alexander E Nosyrev; Christopher W Sutton; Panayiotis D. Mitsias; Aristides Tsatsakis
Journal:  Cells       Date:  2019-08-09       Impact factor: 6.600

4.  Insight into Cisplatin-Resistance Signaling of W1 Ovarian Cancer Cells Emerges mTOR and HSP27 as Targets for Sensitization Strategies.

Authors:  Kathleen Wantoch von Rekowski; Philipp König; Svenja Henze; Martin Schlesinger; Piotr Zawierucha; Radosław Januchowski; Gerd Bendas
Journal:  Int J Mol Sci       Date:  2020-12-03       Impact factor: 5.923

5.  Increased Levels of Plasma Extracellular Heat-Shock Proteins 60 and 70 kDa Characterized Early-Onset Neonatal Sepsis.

Authors:  Arturo Alejandro Canul-Euan; Gibran Zúñiga-González; Janelly Estefania Palacios-Luna; Rolando Maida-Claros; Néstor Fabián Díaz; Patricia Saltigeral-Tigeral; Perla Karina García-May; Oscar Díaz-Ruiz; Héctor Flores-Herrera
Journal:  Front Pediatr       Date:  2021-11-25       Impact factor: 3.418

6.  Construction and Validation of an Immune-Related Risk Score Model for Survival Prediction in Glioblastoma.

Authors:  Wei Ren; Weifeng Jin; Zehua Liang
Journal:  Front Neurol       Date:  2022-03-16       Impact factor: 4.003

Review 7.  OPALS: A New Osimertinib Adjunctive Treatment of Lung Adenocarcinoma or Glioblastoma Using Five Repurposed Drugs.

Authors:  Richard E Kast; Marc-Eric Halatsch; Rafael Rosell
Journal:  Cells       Date:  2021-05-10       Impact factor: 6.600

8.  Ebola Virus VP35 Protein: Modeling of the Tetrameric Structure and an Analysis of Its Interaction with Human PKR.

Authors:  Anupam Banerjee; Pralay Mitra
Journal:  J Proteome Res       Date:  2020-09-18       Impact factor: 4.466

9.  Progress in Natural Compounds/siRNA Co-delivery Employing Nanovehicles for Cancer Therapy.

Authors:  Milad Ashrafizadeh; Ali Zarrabi; Kiavash Hushmandi; Farid Hashemi; Ebrahim Rahmani Moghadam; Mehdi Raei; Mahshad Kalantari; Shima Tavakol; Reza Mohammadinejad; Masoud Najafi; Franklin R Tay; Pooyan Makvandi
Journal:  ACS Comb Sci       Date:  2020-10-23       Impact factor: 3.784

Review 10.  Therapeutic Potential of Selenium in Glioblastoma.

Authors:  Eduard Yakubov; Thomas Eibl; Alexander Hammer; Markus Holtmannspötter; Nicolai Savaskan; Hans-Herbert Steiner
Journal:  Front Neurosci       Date:  2021-05-28       Impact factor: 5.152

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.